Neoral: profile and news

Meta Health Services Inc. Subsidiary Acquires License to Product ... Jan 25, 2006
Sigmasporin(R) will compete with Canada's leading cyclosporine product, Neoral(R), which is marketed by Novartis Pharmaceuticals Canada, Inc. ... - CNW Telbec (Communiqués de presse),

Heart transplant recipients strive to live life to the full Jan 12, 2006
...their lifespan. He said heart recipients have to take immunosuppressants, mainly FK506 and Neoral, for the rest of their lives. The ... - Taipei Times,

Pfizer, Novartis Profits Stall as Demand Slows for Older Drugs Jan 19, 2006
Novartis is looking to reduce dependence on Diovan, whose sales rose 20 percent in the quarter. Sales of the transplant drug Neoral declined 10 percent. ... - Bloomberg

(PZ) Novartis Delivers Strong Performance with Record Results in ... Jan 18, 2006
Transplantation Net sales for the year declined 1% in local currencies based on lower sales of Neoral/Sandimmun (2005: USD 953 million, -6% lc) (Q4: USD 241 ... - Houston Chronicle,

Novartis 4th-Quarter Net Unchanged on Higher Costs (Update3) Jan 19, 2006
...quarter. Revenue from the fungal treatment Lamisil fell 17 percent, while sales of the transplant drug Neoral declined 10 percent. ... - Bloomberg

Novartis 4th-Qtr Net Unchanged; Shares Tumble (Update6) Jan 19, 2006
...in the quarter. Revenue from Lamisil fell 17 percent, while sales of the transplant drug Neoral declined 10 percent. Revenue in ... - Bloomberg

Heart transplant patients celebrate anniversary of their ... Jan 12, 2006
Wu also pointed out that heart transplant recipients must take immunosuppressive drugs such as FK506 or Neoral for the rest of their lives in order to prevent ... - eTaiwan News,

FDA Advisory Committee Recommends Additional Study Data to Support ... Nov 16, 2005
...recipients. It is currently approved in 48 countries for use in combination with Neoral(R) (cyclosporine, USP) MODIFIED. "While ... - PR Newswire (press release),

DCGI may scrap Novartis' Certican clinical trials Nov 29, 2005
...renal advisory committee of the US FDA recommended the provision of additional data from controlled trials with Certican and reduced dose of Neoral regimen in ... - Business Standard,

Novartis delivers strong growth in first nine months of 2005 on ... Oct 18, 2005
Sales for the third quarter were up 7% (+6% lc), supported by unchanged sales of Neoral/Sandimmun (+0% worldwide, +0% lc, -12% US) amid generic competition. ... - Biotech Intelligence (press release),

York Pharma Founds UK Commercial Operations Unit and Appoints ... Sep 1, 2005
...antifungal worldwide. Following the Sandoz/Ciba-Geigy merger he took over the marketing of Neoral® for Novartis (UK). He joined ... - PharmaLive.com (press release),

Drug may keep transplanted kidneys healthier longer Aug 24, 2005
...said. Cyclosporine, sold under the brand names Sandimmune or Neoral by Novartis , and related drugs also can promote heart disease. ... - Reuters AlertNet,

Optimism over Transplant Drug Aug 25, 2005
...is used to prevent rejection of bone marrow and several organs, including heart and liver, and is sold by Novartis under the brand names Sandimmune and Neoral. ... - Red Herring, <**results**>

Commandments from 'The Side Effects Bible' Jun 12, 2005
...find it. If you take Neoral, you'll find it under its generic name, cyclosporine, with a list of its brand-name sisters. But you ... - Palm Beach Post,

IVAX Corporation UK Regulatory Announcement: Regulatory Approval Mar 29, 2005
Cyclosporine oral solution USP, 100 mg/mL is the generic equivalent of Neoral(R) Oral Solution, 100 mg/mL and cyclosporine capsules are the generic equivalent ... - Business Wire

Organ rejection drug to gain Ivax generic version Mar 29, 2005
The Miami-based drug maker said the Food and Drug Administration approval is for generics for Neoral oral solution and capsules, marketed by Novartis ... - South Florida Business Journal

Novartis Gets More Generic Competition Mar 29, 2005
0842 GMT [Dow Jones] Novartis (NVS) gets more generic competition for its former best-selling drug Neoral for transplantation, while growth hormone Sandostatin ... - New Ratings

Novartis Continues to Outpace The Market, Delivering Strong First ... Apr 20, 2005
Sales for the business unit declined 6% (-9% lc) as the Neoral/Sandimmun franchise (-10%; -13% lc; -18% US) was primarily affected by erosion from generic ... - ArriveNet,